ब्रेस्ट कैंसर
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
कहाँ जाना है
इस trial के लिए 1 hospital भारत में मरीज़ ले रहा है।
रजिस्ट्री समरी (तकनीकी)
The Nanosomal Docetaxel Lipid Suspension (NDLS) consists of uniformly sized micro particles of docetaxel suspended in a lipid based formulation. The advantage of such a Lipid Based formulation of Docetaxel is an improvement of the safety profile by eliminating excipients, polysorbate 80 and ethanol which are present in conventional Docetaxel formulations (Taxotere®). This randomized, open-label study is designed to assess the efficacy and safety of Nanosomal Docetaxel Lipid Suspension at the dose of 75 mg/m2 and at the dose of 100 mg/m2 compared to Taxotere® at the dose of 100 mg/m2 in triple-…
स्पॉन्सर: जिना फार्मास्यूटिकल्स इंक।
ClinicalTrials.gov पर NCT03671044
रजिस्ट्री में आखिरी बार 21 मार्च 2025 को अपडेट हुआ · हमने 20 अक्टूबर 2026 को पढ़ा